According to Zhitong Finance App News, Oriental Biotech (688298.SH) disclosed its 2026 third quarter report. The company achieved revenue of 718 million yuan in the first three quarters, an increase of 6.81% over the previous year; net profit loss attributable to shareholders of listed companies of 297 million yuan; loss of 315 million yuan in non-net profit; and basic earnings per share - 1.55 yuan.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.